However, other aspects would make the alternative program less favorable, such as a lack of consideration for the additional benefits of GLP-1/IM use beyond weight-related long-term health benefits (eg, reductions in diabetes-related micro-complications). This evidence concerns the gene GCG and diabetes mellitus.